Drug development

Plant natural products: Back to the future or into extinction?

James D. McChesney, Sylesh K. Venkataraman, John T. Henri

Citations: 376 • 2007

Zebrafish embryos and larvae: A new generation of disease models and drug screens

Shaukat Ali, Danielle L. Champagne, Herman P. Spaink, Michael K. Richardson

Citations: 253 • 2011

Metabolic Stability for Drug Discovery and Development

Collen Masimirembwa, Ulf Bredberg, Tommy B. Andersson

Citations: 219 • 2003

Two approaches to discovering and developing new drugs for Chagas disease

McKerrow Jh, PS Doyle, Engel Jc, LM Podust, Sheilah A. Robertson, Rafaela Salgado Ferreira, T Saxton, Michelle R. Arkin, ID Kerr, LS Brinen, CS Craik

Citations: 173 • 2009

Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases

Kevin Williams, Elizabeth Bilsland, Andrew C. Sparkes, Wayne Aubrey, Michael J. Young, Larisa Soldatova, Kurt De Grave, Jan Ramon, Michaela de Clare, Worachart Sirawaraporn, Stephen G. Oliver, Ross D. King

Citations: 161 • 2015

In Vitro and In Vivo Pharmacological Models to Assess Demyelination and Remyelination

Jean E. Merrill

Citations: 68 • 2008

Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development.

Paweł Baranczewski, Andrzej Stańczak, Antti Kautiainen, Per Sandin, Per‐Olof Edlund

Citations: 63 • 2006

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones

Paul Workman

Citations: 58 • 2003

Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach

Wei Chen, Minyong Chen, Larry S. Barak

Citations: 51 • 2010

PubChem BioAssay: A Decade’s Development toward Open High-Throughput Screening Data Sharing

Yanli Wang, Tiejun Cheng, Stephen H. Bryant

Citations: 51 • 2017

Drug research: from the idea to the product.

J. Kuhlmann

Citations: 47 • 1997

Automated Imaging and other developments in whole‐organism anthelmintic screening

Ross A. Paveley, Q. D. Bickle

Citations: 44 • 2013

High‐content drug screening for rare diseases

Francesco Bellomo, Diego L. Medina, Ester De Leo, A. Panarella, Francesco Emma

Citations: 42 • 2017

Ligand-binding assays : development, validation, and implementation in the drug development arena

Masood N. Khan, John W. A. Findlay

Citations: 39 • 2010

Organoid technology for personalized pancreatic cancer therapy

Axel Bengtsson, Roland Andersson, Jonas Rahm, Karthik Ganganna, Bodil Andersson, Daniel Ansari

Citations: 30 • 2021

Evolution of Drug Development and Regulatory Affairs: The Demonstrated Power of Artificial Intelligence

Zozo Nene, Brian Thabile Flepisi, S Brand, Charlise Basson, Marissa Balmith

Citations: 29 • 2024

Gene Expression Profiling in the Discovery, Optimization and Development of Novel Drugs: One Universal Screening Platform

David K. Bol, Reinhard Ebner

Citations: 25 • 2006

High Throughput Screening Assay for UDP-Glucuronosyltransferase 1A1 Glucuronidation Profiling

Olga V. Trubetskoy, Moshe Finel, Mika Kurkela, Megan Fitzgerald, Noël R. Peters, F. M. Hoffman, V.S. Trubetskoy

Citations: 22 • 2007

A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity

Franz Gruber, Zoe C Johnston, Christopher L. R. Barratt, Paul D. Andrews

Citations: 22 • 2020

Pharmaceutical research

Birgit Fassbender, Timo Fleßner

Citations: 22 • 2009